Linezolid use in German acute care hospitals: results from two consecutive national point prevalence surveys

[1]  C. Kirkpatrick,et al.  Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention. , 2019, The Journal of antimicrobial chemotherapy.

[2]  P. Gastmeier,et al.  Decrease of methicillin resistance in Staphylococcus aureus in nosocomial infections in Germany-a prospective analysis over 10 years. , 2019, The Journal of infection.

[3]  S. Lustig,et al.  Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting , 2018, The Journal of antimicrobial chemotherapy.

[4]  T. Brenner,et al.  [S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults : Focussed summary and supplementary information on antibiotic treatment of critically ill patients]. , 2018, Der Anaesthesist.

[5]  K. Sato,et al.  The impact of earlier intervention by an antimicrobial stewardship team for specific antimicrobials in a single weekly intervention. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  M. Puig-Asensio,et al.  Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Hsin-Yi Lin,et al.  Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance* , 2018, Critical care medicine.

[8]  T. Eckmanns,et al.  Antibiotic consumption in Germany: first data of a newly implemented web-based tool for local and national surveillance , 2018, Journal of Antimicrobial Chemotherapy.

[9]  J. Bender,et al.  Emergence and control of linezolid-resistant Staphylococcus epidermidis in an ICU of a German hospital , 2018, The Journal of antimicrobial chemotherapy.

[10]  P. Gastmeier,et al.  Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany − 10 years of surveillance , 2018, Antimicrobial Resistance & Infection Control.

[11]  P. Gastmeier,et al.  Antimicrobial usage in German acute care hospitals: results of the third national point prevalence survey and comparison with previous national point prevalence surveys , 2018, The Journal of antimicrobial chemotherapy.

[12]  S. Cosgrove,et al.  Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. , 2018, Diagnostic microbiology and infectious disease.

[13]  D. Samuel,et al.  Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France , 2017, The Journal of antimicrobial chemotherapy.

[14]  P. Gastmeier,et al.  The Prevalence of Nosocomial Infection and Antibiotic Use in German Hospitals. , 2017, Deutsches Arzteblatt international.

[15]  A. Kearns,et al.  Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE , 2017, The Journal of antimicrobial chemotherapy.

[16]  S. Harbarth,et al.  Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  Á. Soriano,et al.  Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers , 2017, Antimicrobial Agents and Chemotherapy.

[18]  J. Aguado,et al.  High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus , 2017, The Journal of antimicrobial chemotherapy.

[19]  N. Kohno,et al.  Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[20]  M. Pfaller,et al.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015) , 2017, Antimicrobial Agents and Chemotherapy.

[21]  V. Saini,et al.  Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection , 2017, The Journal of bone and joint surgery. American volume.

[22]  M. Steed,et al.  Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia , 2017, Antimicrobial Agents and Chemotherapy.

[23]  K. Dingle,et al.  Detection of a cfr(B) Variant in German Enterococcus faecium Clinical Isolates and the Impact on Linezolid Resistance in Enterococcus spp. , 2016, PloS one.

[24]  Y. Chuang,et al.  Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  E. Pérez-Nadales,et al.  Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: a before-and-after interventional study. , 2016, The Journal of antimicrobial chemotherapy.

[26]  M. Bassetti,et al.  Safety profiles of old and new antimicrobials for the treatment of MRSA infections , 2016, Expert opinion on drug safety.

[27]  Á. Soriano,et al.  Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention. , 2015, The Journal of antimicrobial chemotherapy.

[28]  O. Zimmermann,et al.  Linezolid resistance in clinical isolates of Staphylococcus epidermidis from German hospitals and characterization of two cfr-carrying plasmids. , 2015, The Journal of antimicrobial chemotherapy.

[29]  M. Dryden.  Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? , 2015, Current opinion in infectious diseases.

[30]  S. Harbarth,et al.  Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. , 2015, The Journal of antimicrobial chemotherapy.

[31]  Hsin-Yi Lin,et al.  Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis , 2014, BMC Infectious Diseases.

[32]  M. Fischer,et al.  Antimicrobial stewardship and linezolid , 2014, International Journal of Clinical Pharmacy.

[33]  J. Rello,et al.  European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  D. Nathwani,et al.  European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[35]  P. Gastmeier,et al.  Nosocomial infection and antibiotic use: a second national prevalence study in Germany. , 2013, Deutsches Arzteblatt international.

[36]  J. Ariza,et al.  Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. , 2013, Diagnostic microbiology and infectious disease.

[37]  R. Humphries,et al.  The emerging problem of linezolid-resistant Staphylococcus. , 2013, The Journal of antimicrobial chemotherapy.

[38]  M. Dryden.  Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. , 2011, The Journal of antimicrobial chemotherapy.

[39]  P. Montravers,et al.  Antimicrobial Treatmdent of "Complicated" Intra-Abdominal Infections and The New IDSA Guidelines - A Commentary and an Alternative European Approach According to Clinical Definitions , 2011, European journal of medical research.

[40]  A. Cánovas,et al.  Linezolid plus Rifampin as a Salvage Therapy in Prosthetic Joint Infections Treated without Removing the Implant , 2011, Antimicrobial Agents and Chemotherapy.

[41]  T. Welte,et al.  Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy , 2010, European journal of medical research.

[42]  E. P. Dellinger,et al.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..